Thyroid Cancer 101: New Combination Therapy For BRAF-mutated Anaplastic Thyroid Cancer

Thyroid Cancer 101: New Combination Therapy For BRAF-mutated Anaplastic Thyroid Cancer

Thyroid Cancer 101: New Combination Therapy For BRAF-mutated Anaplastic Thyroid Cancer

Thyroid Cancer 101: New Combination Therapy For BRAF-mutated Anaplastic Thyroid Cancer

 

Dr.Guttler’s comments:

ATC is one of the fastest growing cancers. Usual death in months.

If you want to go in a clinical trial act fast, but remember there are many serious complications from these drugs. It may not be worth the few extra months with side effects from treatment versus spending the time to get your life in order. I have never had a ATC patient elect to get chemotherapy,surgery and radiation instead of just letting the disease take it’s course.

Dr.G.

310-393-8860

thyroid.manager@protonmail.com

FDA Oks Tafinlar-Mekinist Combination For BRAF-mutated Anaplastic Thyroid Cancer

 

tafinlar_mekinist_logo_4x

image

CT of an ATC

 

(RTTNews.com) – The U.S. Food and Drug Administration approved Tafinlar or dabrafenib and Mekinist or trametinib, administered together, for the treatment of anaplastic thyroid cancer or ATC that cannot be removed by surgery or has spread to other parts of the body or metastatic, and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive). The FDA granted this approval to Novartis Pharmaceuticals Corporation.

Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid gland. Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer. The National Institutes of Health estimates there will be 53,990 new cases of thyroid cancer and an estimated 2,060 deaths from the disease in the United States in 2018. Anaplastic thyroid cancer accounts for about 1 to 2 percent of all thyroid cancers.

Both Tafinlar and Mekinist are also approved for use, alone or in combination, to treat BRAF V600 mutation-positive metastatic melanoma. Additionally, Tafinlar and Mekinist are approved for use, in combination, to treat BRAF V600E mutation-positive, metastatic non-small cell lung cancer.

The side effects of Tafinlar and Mekinist in patients with ATC are consistent with those seen in other cancers when the two drugs are used together. Common side effects include fever (pyrexia), rash, chills, headache, joint pain (arthralgia), cough, fatigue, nausea, vomiting, diarrhea, myalgia (muscle pain), dry skin, decreased appetite, edema, hemorrhage, high blood pressure (hypertension) and difficulty breathing (dyspnea).

Severe side effects of Tafinlar include the development of new cancers, growth of tumors in patients with BRAF wild-type tumors, serious bleeding problems, heart problems, severe eye problems, fever that may be severe, serious skin reactions, high blood sugar or worsening diabetes, and serious anemia.

Severe side effects of Mekinist include the development of new cancers; serious bleeding problems; inflammation of intestines and perforation of the intestines; blood clots in the arms, legs or lungs; heart problems; severe eye problems; lung or breathing problems; fever that may be severe; serious skin reactions; and high blood sugar or worsening diabetes.

The FDA warned that Both Tafinlar and Mekinist can cause harm to a developing fetus; women should be advised of the potential risk to the fetus and to use effective contraception.

Image of a PET scan from Dr.Gary Clayman’s thyroid cancer center of a patient with ATC.

Add Your Comment

Contact Info
1328 16th Street, Santa Monica, CA 90404
Monday – Friday
9:00 AM to 5:00 PM
(310) 393-8860